Baqsimi™ (glucagon) nasal powder


This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BAQSIMI™ (glucagon) nasal powder: Overdose

If overdosage occurs with Baqsimi (glucagon nasal powder), the patient may experience gastrointestinal or cardiac effects, and serum potassium levels should be monitored.

Detailed Information

If overdosage occurs with Baqsimi, the patient may experience

  • nausea

  • vomiting

  • inhibition of GI tract motility

  • increase in BP, and

  • increase in pulse rate.1

In case of suspected overdosing, serum potassium levels

  • may decrease

  • should be monitored, and

  • should be corrected if needed.1

If the patient develops a dramatic increase in BP, phentolamine mesylate has been shown to be effective in lowering BP for the short time that control would be needed.1

Enclosed Prescribing Information

BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly


1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


Baqsimi = Baqsimi™ (glucagon) nasal powder

BP = blood pressure

GI = gastrointestinal

Date of Last Review: July 24, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical